Skip to main content
. 2022 Oct 4;4(5):fcac247. doi: 10.1093/braincomms/fcac247

Figure 2.

Figure 2

Cumulative incidence of Alzheimer’s disease and related dementia in patients treated with PDE5 inhibitors versus ERAs after 1:1 propensity score matching, Medicare data 2007–2018. Analysis 1: ‘As-treated’ follow-up approach; Analysis 2: ‘As-started’ follow-up approach incorporating a 6-month induction period; Analysis 3: Incorporating a 6-month ‘symptom to diagnosis’ period’ and Analysis 4: Alternate outcome definition (See Methods for additional description of analytic approach).